Switch theme
Sign up to access all valuation multiples
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
2013
31
Last FY Revenue $10.1M
Last FY EBITDA -$19.9M
$20.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Relief Therapeutics achieved revenue of $10.1M and an EBITDA of -$19.9M.
Relief Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Relief Therapeutics valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $10.1M | XXX | XXX | XXX |
| Gross Profit | XXX | $7.0M | XXX | XXX | XXX |
| Gross Margin | XXX | 69% | XXX | XXX | XXX |
| EBITDA | XXX | -$19.9M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -197% | XXX | XXX | XXX |
| EBIT | XXX | -$9.5M | XXX | XXX | XXX |
| EBIT Margin | XXX | -94% | XXX | XXX | XXX |
| Net Profit | XXX | -$20.6M | XXX | XXX | XXX |
| Net Margin | XXX | -203% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Relief Therapeutics's stock price is CHF 2 (or $3).
Relief Therapeutics has current market cap of CHF 29.6M (or $35.5M), and EV of CHF 16.7M (or $20.0M).
See Relief Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $20.0M | $35.5M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Relief Therapeutics has market cap of $35.5M and EV of $20.0M.
Relief Therapeutics's trades at 2.0x EV/Revenue multiple, and -1.0x EV/EBITDA.
Equity research analysts estimate Relief Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Relief Therapeutics's P/E ratio is not available.
See valuation multiples for Relief Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $35.5M | XXX | $35.5M | XXX | XXX | XXX |
| EV (current) | $20.0M | XXX | $20.0M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -1.0x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -2.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -1.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -5.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRelief Therapeutics's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.5M for the same period.
Relief Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Relief Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Relief Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -197% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 163% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Relief Therapeutics acquired XXX companies to date.
Last acquisition by Relief Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Relief Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Relief Therapeutics founded? | Relief Therapeutics was founded in 2013. |
| Where is Relief Therapeutics headquartered? | Relief Therapeutics is headquartered in Switzerland. |
| How many employees does Relief Therapeutics have? | As of today, Relief Therapeutics has 31 employees. |
| Is Relief Therapeutics publicy listed? | Yes, Relief Therapeutics is a public company listed on SWX. |
| What is the stock symbol of Relief Therapeutics? | Relief Therapeutics trades under RLF ticker. |
| When did Relief Therapeutics go public? | Relief Therapeutics went public in 2013. |
| Who are competitors of Relief Therapeutics? | Similar companies to Relief Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Relief Therapeutics? | Relief Therapeutics's current market cap is $35.5M |
| Is Relief Therapeutics profitable? | Yes, Relief Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
